创模生物科技(北京)有限公司

CN / En

NEWS

Introduction to the SCID Mouse NK Efficacy Model of InnoModels Biotechnology

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-27 15:57
  • Views:

(Summary description)The SCID mouse is a mouse model with an autosomal recessive purist Prkdcscid mutant that causes mice to exhibit severe combined immunodeficiency.SCID mice lack mature T and B lymphocytes but retain some functions of macrophages and NK cells. This model is uniquely advantageous in the efficacy assessment of NK cell-associated drugs because NK cells can function independently in the absence of interference from other immune cells

Introduction to the SCID Mouse NK Efficacy Model of InnoModels Biotechnology

(Summary description)The SCID mouse is a mouse model with an autosomal recessive purist Prkdcscid mutant that causes mice to exhibit severe combined immunodeficiency.SCID mice lack mature T and B lymphocytes but retain some functions of macrophages and NK cells. This model is uniquely advantageous in the efficacy assessment of NK cell-associated drugs because NK cells can function independently in the absence of interference from other immune cells

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-27 15:57
  • Views:
Information

Introduction
With the rapid development of biomedicine, especially the continuous progress in the field of immunotherapy, it is especially important to find efficient and reliable experimental models to verify drug efficacy. InnoModels Biotechnology (Beijing) Co., Ltd. has made remarkable breakthroughs in the field of immunotherapy, especially in natural killer (NK) cell immunotherapy. The company has successfully developed an NK efficacy model based on SCID (Severe Combined Immunodeficiency) mice, which provides strong support for the development of NK cell-related drugs.
Overview of the SCID mouse model
The SCID mouse is a mouse model with an autosomal recessive purist Prkdcscid mutant that causes mice to exhibit severe combined immunodeficiency.SCID mice lack mature T and B lymphocytes but retain some functions of macrophages and NK cells. This model is uniquely advantageous in the efficacy assessment of NK cell-associated drugs because NK cells can function independently in the absence of interference from other immune cells.
Advantages of the InnoModels SCID Mouse NK Efficacy Model
1. High homology
Mouse NK cells are highly homologous to human NK cells in terms of their development, functional properties and acquisition of memory-like features. Therefore, the SCID mouse model has high accuracy in simulating human NK cell responses, providing a solid foundation for preclinical evaluation of NK cell immunotherapy drugs.
2. Efficient NK cell reconstitution
By optimizing the experimental conditions, InnoModels Biotechnology has successfully achieved efficient NK cell reconstitution in SCID mice. This not only improves the sensitivity of drug evaluation, but also makes the pharmacodynamic response closer to the actual clinical situation.
3. Stable pharmacodynamic response
The SCID mouse model shows high stability during drug evaluation and can accurately reflect the effects of different drugs on NK cells. In addition, the model can also conveniently predict the efficacy of different donors, the degree of matching with tumor cells, and their ability to trigger graft-versus-host disease (GVHD), thus improving the reliability and reproducibility of the experimental results.
Model Application and Experimental Procedure
Applications
The SCID mouse NK efficacy model is widely used in the preclinical evaluation of NK cell-related drugs, including immune checkpoint inhibitors, NK cell activators, and ADCC drugs targeting tumor-specific targets. In addition, the model can also be used to validate the efficacy of innovative therapies such as CAR-NK cell therapy.

 


Experimental Procedure
1. **Model preparation**: select healthy SCID mice as experimental subjects, and ensure that the mice do not have other immunodeficiencies or diseases.
2. **NK Cell Reconstruction**: Through specific experimental methods, NK cells are reconstructed in the mice to reach a certain number and activity level.
3. **Drug administration**: mice are injected with the NK cell-related drug to be evaluated according to the experimental design.
4. **Drug Efficacy Assessment**: At different time points after drug administration, blood and tissue samples of mice are collected to detect changes in the number, activity and function of NK cells, and to assess the growth of tumor cells at the same time.
5. **DATA ANALYSIS**: Based on the experimental results, analyze the effect of the drug on NK cells and its anti-tumor effect, and provide data support for further development of the drug.
Conclusion
The SCID mouse NK efficacy model successfully developed by InnoModels Biotechnology provides a reliable platform for preclinical evaluation of NK cell immunotherapy drugs. The model not only has the advantages of high homology, efficient NK cell reconstitution and stable pharmacodynamic response, but also is widely used in the development of many NK cell-related drugs. With the deepening of the research, it is believed that the model will play an even more important role in the future and promote the further development of the immunotherapy field.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司